Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM · NASDAQ Global Select
-$0.39 today
Vol 0.31M · Avg 0.26M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-23.0%
avg -37.3%
ROIC
-25.3%
avg -30.4%
ROA
-21.7%
avg -22.6%
Analysis
ROA is currently the strongest return metric at -21.7% versus its period average of -22.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Carmine N. Stengone | President, Chief Executive Officer & Director | $1.12M | — | 50 | $120,917.00 | 0.32% |
Timothy R. Watkins | Chief Medical Officer & Head of Development | $778,767.00 | — | 52 | $0.00 | <0.01% |
Peter T. Slover | Chief Financial Officer | $737,635.00 | — | 51 | $192,000.00 | 0.51% |
John Healy | General Counsel & Corporate Secretary | $612,780.00 | — | 54 | $206,411.00 | 0.55% |
Daniel S. Lorrain | Chief Science Officer | $565,024.00 | — | 57 | $139,372.00 | 0.37% |
Jennifer Patterson | Vice President of Human Resources | — | — | — | — | — |
Julie S. Iwashita | Senior Vice President of Clinical Operations | — | — | — | $139,372.00 | 0.37% |
Steve E. Kunszabo | Senior Director of Investor Relations & Corporate Communications | — | — | — | — | — |
Kristina Haeckl Rac | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Austin Chen | Senior Vice President & Head of Research | — | — | — | — | — |
Morgan Paulsen | Senior Manager of Accounting | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
21
$792,271.51
Net Sentiment
$792,271.51
Net selling
Most Active
Lorrain Daniel S.
14 transactions
1–10 of 21
Analysis
Insiders reported 0 buys worth $0.00 and 21 sells worth $792,271.51 over the last 12 months. That adds up to net selling of $792,271.51. Lorrain Daniel S. was the most active insider with 14 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.29B
Alto Neuroscience, Inc.
NYSE:ANRO
$779.61M
Candel Therapeutics, Inc.
NASDAQ:CADL
$438.11M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$389.07M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$350.33M
Amarin Corporation plc
NASDAQ:AMRN
$334.44M
Silence Therapeutics plc
NASDAQ:SLN
$324.73M
AC Immune S.A.
NASDAQ:ACIU
$240.19M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$116.42M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.79M
Who manages CTNM?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) lists 11 active executives. The top listed executive is Jennifer Patterson, Vice President of Human Resources.
Are CTNM insiders buying or selling?
Recent insider activity shows net buying of $24.50M.
Explore More
Continue the stock analysis
Jump to another research area for this company.